Cargando…
Novel non-carbohydrate O-GlcNAcase inhibitors with CNS drug properties as potential treatment for Alzheimer’s disease and tauopathies
Autores principales: | Hering, Heike, Graham, Danielle, Ousson, Solenne, Neny, Maud, Gray, Audrey, Giacomozzi, Brandy, Joyce, John, Dutt, Vikram, Busch, Michael, Cameron, Andrew, Liu-Bujalski, Leslie, Yu, Henry, Tian, Hui, Shearman, Mark, Quattropani, Anna, Permanne, Bruno, Wiessner, Christoph, Beher, Dirk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846928/ http://dx.doi.org/10.1186/1750-1326-8-S1-O17 |
Ejemplares similares
-
O-GlcNAcase Inhibitor ASN90 is a Multimodal
Drug Candidate for Tau and α-Synuclein Proteinopathies
por: Permanne, Bruno, et al.
Publicado: (2022) -
Structural and functional insight into human O-GlcNAcase
por: Roth, Christian, et al.
Publicado: (2017) -
O-GlcNAcase contributes to cognitive function in Drosophila
por: Muha, Villo, et al.
Publicado: (2020) -
Differential Effects of an O-GlcNAcase Inhibitor on Tau Phosphorylation
por: Yu, Yang, et al.
Publicado: (2012) -
Synergy of Peptide and Sugar in O-GlcNAcase Substrate Recognition
por: Schimpl, Marianne, et al.
Publicado: (2012)